Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Global X Defense Tech ETF (SHLD) Price & Performance

Amylx Pharmaceuticals IncTrade
Global X Defense Tech ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Global X Defense Tech ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while Global X Defense Tech ETF trades at $69.49. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.

AMLXSHLD
Market Cap
$2.64B
Sector
HealthSector/Thematic
52-Week High
$24.19$78.02
52-Week Low
$7.82$58.20
Enterprise Value
$2.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Global X Defense Tech ETF

SHLD (Global X Defense Tech ETF) trades at $69.04, up 1.86% with bullish technical signals from moving averages but overbought RSI readings. The ETF benefits from institutional accumulation and positive sentiment around global defense spending increases. Recent news highlights multiple institutional investors increasing positions, while technical analysis shows strong support at $68 and resistance at $70.

Outlook remains positive given geopolitical tensions driving defense budgets higher, though overbought conditions suggest potential near-term consolidation. Key risks include political uncertainty and valuation concerns after recent gains. The ETF offers diversified exposure to defense technology with institutional confidence supporting the long-term thesis.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Global X Defense Tech ETF

SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.

Read more on SHLD